208 related articles for article (PubMed ID: 31792572)
1. Digital versus analogue PET in [
Alberts I; Prenosil G; Sachpekidis C; Weitzel T; Shi K; Rominger A; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):614-623. PubMed ID: 31792572
[TBL] [Abstract][Full Text] [Related]
2. The influence of digital PET/CT on diagnostic certainty and interrater reliability in [
Alberts I; Hünermund JN; Sachpekidis C; Mingels C; Fech V; Bohn KP; Rominger A; Afshar-Oromieh A
Eur Radiol; 2021 Oct; 31(10):8030-8039. PubMed ID: 33856522
[TBL] [Abstract][Full Text] [Related]
3. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Matched-Pair Comparison of
Rauscher I; Krönke M; König M; Gafita A; Maurer T; Horn T; Schiller K; Weber W; Eiber M
J Nucl Med; 2020 Jan; 61(1):51-57. PubMed ID: 31253741
[No Abstract] [Full Text] [Related]
6. Performance of [
Afshar-Oromieh A; da Cunha ML; Wagner J; Haberkorn U; Debus N; Weber W; Eiber M; Holland-Letz T; Rauscher I
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2925-2934. PubMed ID: 33543325
[TBL] [Abstract][Full Text] [Related]
7.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
8. Dynamic patterns of [
Alberts I; Sachpekidis C; Gourni E; Boxler S; Gross T; Thalmann G; Rahbar K; Rominger A; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):160-167. PubMed ID: 31628514
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Digital versus Analog
Rovera G; Grimaldi S; Dall'Armellina S; Zotta M; Finessi M; Passera R; Deandreis D
Diagnostics (Basel); 2023 Nov; 13(23):. PubMed ID: 38066776
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of
Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
[TBL] [Abstract][Full Text] [Related]
13. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
14. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer.
Sachpekidis C; Kopka K; Eder M; Hadaschik BA; Freitag MT; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2016 Nov; 41(11):e473-e479. PubMed ID: 27607173
[TBL] [Abstract][Full Text] [Related]
16. Matched-Pair Comparison of
Kroenke M; Mirzoyan L; Horn T; Peeken JC; Wurzer A; Wester HJ; Makowski M; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2021 Aug; 62(8):1082-1088. PubMed ID: 33277394
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
18. Application of [
Dadgar H; Emami F; Norouzbeigi N; Vafaee MS; Jafari E; Gholamrezanezhad A; Assadi M; Ahmadzadehfar H
Mol Imaging Biol; 2020 Aug; 22(4):1062-1069. PubMed ID: 31758511
[TBL] [Abstract][Full Text] [Related]
19. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
20. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]